Synergy Pharmaceuticals to Present Data on SP-333 at Digestive Disease Week 2014

  Synergy Pharmaceuticals to Present Data on SP-333 at Digestive Disease Week   2014  Digestive Disease Week 2014  Business Wire  NEW YORK -- May 1, 2014  Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that updated preclinical data on the company’s second-generation uroguanylin analog, SP-333, will be presented during a poster session at Digestive Disease Week (DDW) in Chicago, May 3 - May 6, 2014.  The following poster will be presented at DDW on Saturday, May 3, 2014, 8am – 5pm in McCormick Place - South Hall:  Oral Treatment with SP-333, an Agonist of Guanylate Cyclase-C, Dramatically Ameliorates Methadone-Induced Bowel Dysfunction in Rats (Palejwala, Vaseem A.; Saykhedkar, Sayali; Joshi, Apoorva; Patwa, Viren; Vemalapally, Laxmi; Thadi, Anusha; Foss, John A.; Shailubhai, Kunwar ^ - Poster #Sa2013)  About SP-333  SP-333 is Synergy’s second-generation uroguanylin analog in development to treat patients with opioid-induced constipation (OIC) and ulcerative colitis (UC). SP-333 is a synthetic analog of the naturally occurring gastrointestinal hormone, uroguanylin, designed as a highly stable and potent peptide that is resistant to proteolysis in gastric and intestinal fluids. SP-333 has successfully completed phase I single and multiple ascending dose studies in healthy volunteers and is currently in a phase 2 clinical trial for OIC. Synergy is also developing a unique formulation of SP-333 for treating GI inflammation in patients with UC. For more information, please visit  Contact:  Synergy Pharmaceuticals Inc. Media: Gem Gokmen Office: 212-584-7610 Mobile: 646-637-3208 or Investors: Bernard Denoyer Office: 212-297-0020 Mobile: 203-300-8147